GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Institutional Ownership

Nicox (XPAR:ALCOX) Institutional Ownership : 3.06% (As of May. 05, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Nicox Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nicox's institutional ownership is 3.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nicox's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nicox's Float Percentage Of Total Shares Outstanding is 0.00%.


Nicox Institutional Ownership Historical Data

The historical data trend for Nicox's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Institutional Ownership Chart

Nicox Historical Data

The historical data trend for Nicox can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 3.14 3.14 3.00 3.00 3.00 3.42 3.16 3.16 3.06 3.06

Nicox Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Nicox Business Description

Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines